Why Attend the 3rd CRISPR-Based Therapy Analytical Development Summit?
❝
Nice event to connect with CRISPR-based drug developers who have hands-on experience developing drug products from preclinical to clinical stages
Director of Data Science and Tech Platform, Scribe Therapeutics
2024 Speaker
Now in its third year, this summit is the only dedicated platform where analytical, QC, and regulatory experts converge to tackle CRISPR-specific challenges that are sidelined at broader CMC and analytical meetings.
Join analytical and regulatory experts sharing real-world case studies, and leave equipped with the tools, insights, and connections to confidently advance your CRISPR programs to the clinic and beyond.
Don’t Miss Out On
Gaining practical insights into designing, validating, and scaling potency assays tailored specifically for CRISPR-edited products, with a focus on regulatory expectations and assay performance.
Exploring advanced sequencing and bioinformatics tools for detecting off-target edits, structural variants, and impurities, ensuring the integrity and safety of gene-edited therapies.
Understanding analytical strategies for emerging delivery vehicles such as LNPs, RNPs, and viral-like particles, including how to evaluate delivery efficiency and manage associated toxicity.
Discovering how automation and machine learning are being integrated into analytical workflows to enhance reproducibility, reduce manual errors, and streamline assay development.
Benchmarking analytical approaches against leading developers through real-world case studies and expert-led discussions featuring Beam, Mammoth, Excision, and KSQ Therapeutics.